Neogen Corporation Peer Comparison
Metric | Value | Ranking | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $2.2 Billion | 9/15 | IQV $35.9B |
ICLR $15.4B |
MEDP $10.5B |
QGEN $8.7B |
RDNT $4.6B |
SYNH $4.5B |
SHC $3.9B |
OLK $3.2B |
NEOG $2.2B |
MYGN $1.2B |
ACRS $232.2M |
SERA $140.7M |
FONR $101.6M |
XGN $84.5M |
BNR $64.1M |
Gross Margin | 49% | 10/15 | RDNT 100% |
ACRS 85% |
BNR 71% |
MYGN 70% |
QGEN 61% |
OLK 61% |
XGN 56% |
SHC 55% |
SERA 55% |
NEOG 49% |
FONR 40% |
IQV 35% |
ICLR 25% |
SYNH 22% |
MEDP -38% |
Profit Margin | -100% | 13/15 | QGEN 20% |
MEDP 18% |
FONR 13% |
IQV 11% |
ICLR 10% |
SHC 6% |
RDNT 5% |
SYNH 0% |
MYGN -10% |
BNR -28% |
XGN -40% |
OLK -56% |
NEOG -100% |
ACRS -100% |
SERA -100% |
EBITDA margin | -198% | 13/15 | MEDP 118% |
RDNT 93% |
SHC 43% |
QGEN 35% |
FONR 29% |
IQV 26% |
ICLR 19% |
SYNH 8% |
MYGN -1% |
BNR -30% |
XGN -37% |
OLK -73% |
NEOG -198% |
ACRS -241% |
SERA -30559% |
Quarterly Revenue | $231.3 Million | 8/15 | IQV $4.0B |
ICLR $2.0B |
SYNH $1.4B |
MEDP $533.3M |
QGEN $501.9M |
RDNT $461.1M |
SHC $285.5M |
NEOG $231.3M |
MYGN $213.3M |
BNR $29.6M |
OLK $28.6M |
FONR $25.0M |
XGN $12.5M |
ACRS $4.3M |
SERA $29,000 |
Quarterly Earnings | -$456.3 Million | 15/15 | IQV $437.0M |
ICLR $197.1M |
QGEN $98.1M |
MEDP $96.5M |
RDNT $20.9M |
SHC $17.0M |
FONR $3.1M |
SYNH $793,000 |
XGN -$5.0M |
ACRS -$7.6M |
SERA -$7.9M |
BNR -$8.2M |
OLK -$16.0M |
MYGN -$22.1M |
NEOG -$456.3M |
Quarterly Free Cash Flow | $78.7 Million | 5/15 | ICLR $370.1M |
MEDP $167.4M |
RDNT $161.5M |
QGEN $138.0M |
NEOG $78.7M |
SHC $59.2M |
ACRS $22.0M |
FONR -$148,000 |
XGN -$2.3M |
MYGN -$5.6M |
SERA -$6.3M |
BNR -$7.0M |
OLK -$8.2M |
SYNH -$51.6M |
IQV -$0 |
Trailing 4 Quarters Revenue | $913.8 Million | 9/15 | FONR $102.9B |
IQV $15.4B |
ICLR $6.2B |
SYNH $5.4B |
MEDP $2.1B |
QGEN $2.0B |
RDNT $1.8B |
SHC $1.1B |
NEOG $913.8M |
MYGN $823.6M |
OLK $171.4M |
BNR $117.7M |
XGN $55.8M |
ACRS $27.1M |
SERA $94,000 |
Trailing 4 Quarters Earnings | -$476.3 Million | 15/15 | IQV $4.0B |
ICLR $2.0B |
SYNH $1.4B |
MEDP $533.3M |
QGEN $501.9M |
RDNT $461.1M |
SHC $285.5M |
NEOG $231.3M |
MYGN $213.3M |
BNR $29.6M |
OLK $28.6M |
FONR $25.0M |
XGN $12.5M |
ACRS $4.3M |
SERA $29,000 |
Quarterly Earnings Growth | -12985% | 15/15 | RDNT 217879% |
SHC 224% |
BNR 80% |
ACRS 74% |
MYGN 64% |
MEDP 37% |
QGEN 26% |
ICLR 20% |
XGN 7% |
IQV -7% |
SERA -10% |
OLK -14% |
FONR -64% |
SYNH -99% |
NEOG -12985% |
Annual Earnings Growth | -46707% | 15/15 | FONR 196749% |
RDNT 102% |
MYGN 72% |
ACRS 69% |
MEDP 44% |
BNR 25% |
SHC 24% |
XGN 17% |
SERA 17% |
ICLR 4% |
IQV 0% |
SYNH -67% |
QGEN -71% |
OLK -1544% |
NEOG -46707% |
Quarterly Revenue Growth | 1% | 9/15 | RDNT 461042% |
FONR 1134% |
MYGN 11% |
MEDP 8% |
SHC 8% |
QGEN 5% |
OLK 4% |
IQV 2% |
NEOG 1% |
BNR 1% |
SYNH 0% |
ICLR -1% |
XGN -7% |
SERA -31% |
ACRS -53% |
Annual Revenue Growth | 0% | 9/15 | FONR 129585% |
ACRS 82% |
RDNT 46% |
MYGN 11% |
MEDP 10% |
SHC 9% |
IQV 2% |
SYNH 1% |
NEOG 0% |
QGEN 0% |
XGN 0% |
BNR -10% |
OLK -15% |
ICLR -23% |
SERA -77% |
Cash On Hand | $140.2 Million | 7/15 | IQV $1.7B |
QGEN $973.0M |
RDNT $748.9M |
ICLR $695.5M |
MEDP $656.9M |
SHC $306.7M |
NEOG $140.2M |
BNR $114.7M |
OLK $109.3M |
MYGN $99.9M |
SYNH $82.2M |
FONR $54.2M |
ACRS $47.7M |
XGN $22.0M |
SERA $2.7M |
Short Term Debt | $2.6 Million | 11/15 | IQV $1.1B |
QGEN $555.3M |
RDNT $82.1M |
SYNH $68.3M |
ICLR $29.8M |
SHC $22.9M |
MYGN $13.5M |
FONR $7.6M |
BNR $6.4M |
OLK $4.1M |
NEOG $2.6M |
XGN $1.5M |
SERA $305,000 |
ACRS -$0 |
MEDP -$670.9M |
Long Term Debt | $889.9 Million | 6/15 | ICLR $3.4B |
SYNH $2.8B |
SHC $2.3B |
RDNT $1.7B |
QGEN $1.4B |
NEOG $889.9M |
IQV $173.0M |
MYGN $129.6M |
MEDP $128.3M |
FONR $37.4M |
OLK $22.1M |
XGN $21.8M |
BNR $16.8M |
SERA $168,000 |
ACRS $0 |
PE | -1.00 | 9/15 | QGEN 94.02 |
RDNT 90.38 |
SYNH 62.59 |
SHC 54.81 |
ICLR 28.98 |
MEDP 28.60 |
IQV 26.15 |
FONR 0.00 |
NEOG -1.00 |
MYGN -1.00 |
ACRS -1.00 |
XGN -1.00 |
BNR -1.00 |
OLK -1.00 |
SERA -1.00 |
PS | 2.36 | 9/15 | SERA 1497.15 |
OLK 18.91 |
ACRS 8.58 |
MEDP 5.05 |
QGEN 4.44 |
SHC 3.46 |
RDNT 2.59 |
ICLR 2.47 |
NEOG 2.36 |
BNR 2.36 |
IQV 2.33 |
XGN 1.52 |
MYGN 1.45 |
SYNH 0.82 |
FONR 0.00 |
PB | 0.81 | 13/15 | MEDP 11.86 |
SHC 8.25 |
OLK 7.03 |
XGN 6.57 |
IQV 5.92 |
RDNT 4.10 |
SERA 2.58 |
QGEN 2.48 |
ACRS 1.78 |
MYGN 1.63 |
ICLR 1.58 |
SYNH 1.28 |
NEOG 0.81 |
FONR 0.64 |
BNR 0.43 |
PC | 15.39 | 7/15 | SYNH 54.25 |
SERA 52.43 |
OLK 29.67 |
ICLR 22.14 |
IQV 21.10 |
MEDP 15.92 |
NEOG 15.39 |
SHC 12.64 |
MYGN 11.93 |
QGEN 8.98 |
RDNT 6.13 |
ACRS 4.87 |
XGN 3.83 |
FONR 1.87 |
BNR 0.56 |
Liabilities to Equity | 0.52 | 9/15 | SHC 5.70 |
IQV 3.43 |
RDNT 2.41 |
XGN 2.39 |
MEDP 1.36 |
SYNH 1.31 |
QGEN 0.78 |
ICLR 0.76 |
NEOG 0.52 |
BNR 0.52 |
MYGN 0.48 |
SERA 0.45 |
ACRS 0.40 |
FONR 0.32 |
OLK 0.18 |
ROA | -0.12 | 12/15 | FONR 11508% | MEDP 18% | IQV 5% | ICLR 3% | RDNT 2% | SHC 2% | SYNH 1% | QGEN 1% | OLK -6% | BNR -10% | MYGN -11% | NEOG -12% | ACRS -20% | XGN -39% | SERA -41% |
ROE | -0.18 | 12/15 | FONR 14482% |
MEDP 41% |
IQV 23% |
SHC 15% |
RDNT 6% |
ICLR 5% |
QGEN 3% |
SYNH 2% |
OLK -7% |
BNR -15% |
MYGN -16% |
NEOG -18% |
ACRS -28% |
SERA -59% |
XGN -132% |
Current Ratio | 2.93 | 6/15 | OLK 6.68 |
FONR 3.97 |
ACRS 3.49 |
SERA 3.24 |
MYGN 3.09 |
NEOG 2.93 |
BNR 2.93 |
ICLR 2.31 |
QGEN 2.29 |
SYNH 1.76 |
MEDP 1.73 |
RDNT 1.52 |
XGN 1.42 |
IQV 1.29 |
SHC 1.18 |
Quick Ratio | 0.10 | 12/15 | QGEN 94.02 |
RDNT 90.38 |
SYNH 62.59 |
SHC 54.81 |
ICLR 28.98 |
MEDP 28.60 |
IQV 26.15 |
FONR 0.00 |
NEOG -1.00 |
MYGN -1.00 |
ACRS -1.00 |
XGN -1.00 |
BNR -1.00 |
OLK -1.00 |
SERA -1.00 |
Long Term Debt to Equity | 0.33 | 7/15 | SHC} 4.97 |
RDNT} 1.85 |
XGN} 1.69 |
SYNH} 0.81 |
QGEN} 0.39 |
ICLR} 0.35 |
NEOG} 0.33 |
FONR} 0.22 |
MYGN} 0.18 |
MEDP} 0.15 |
BNR} 0.11 |
OLK} 0.05 |
IQV} 0.03 |
ACRS} 0.00 |
SERA} 0.00 |
Debt to Equity | 0.33 | 7/15 | SHC 5.01 |
RDNT 1.94 |
XGN 1.81 |
SYNH 0.83 |
QGEN 0.54 |
ICLR 0.35 |
NEOG 0.33 |
FONR 0.24 |
IQV 0.22 |
MYGN 0.20 |
BNR 0.16 |
MEDP 0.15 |
OLK 0.06 |
SERA 0.01 |
ACRS 0.00 |
Burn Rate | 0.28 | 12/15 | FONR 214.93 |
BNR 27.48 |
RDNT 11.38 |
QGEN 10.21 |
ACRS 6.28 |
OLK 6.11 |
SHC 3.74 |
XGN 3.51 |
MYGN 3.26 |
SYNH 0.64 |
SERA 0.34 |
NEOG 0.28 |
MEDP -2.54 |
IQV -11.83 |
ICLR -12.98 |
Cash to Cap | 0.06 | 9/15 | BNR 1.79 |
FONR 0.53 |
XGN 0.26 |
ACRS 0.21 |
RDNT 0.16 |
QGEN 0.11 |
MYGN 0.08 |
SHC 0.08 |
NEOG 0.06 |
MEDP 0.06 |
IQV 0.05 |
ICLR 0.05 |
OLK 0.03 |
SYNH 0.02 |
SERA 0.02 |
CCR | -0.17 | 12/15 | RDNT 7.72 |
SHC 3.48 |
ICLR 1.88 |
MEDP 1.74 |
QGEN 1.41 |
BNR 0.85 |
SERA 0.80 |
OLK 0.52 |
XGN 0.46 |
MYGN 0.25 |
FONR -0.05 |
NEOG -0.17 |
ACRS -2.90 |
SYNH -65.12 |
IQV |
EV to EBITDA | -6.36 | 10/15 | SYNH} 64.31 |
QGEN} 54.43 |
SHC} 48.26 |
ICLR} 46.34 |
IQV} 34.72 |
MEDP} 15.84 |
RDNT} 13.05 |
FONR} 12.05 |
BNR} 9.91 |
NEOG} -6.36 |
SERA} -15.63 |
ACRS} -17.63 |
XGN} -18.38 |
OLK} -151.26 |
MYGN} -561.30 |
EV to Revenue | 3.19 | 7/15 | SERA 1473.63 |
OLK 18.43 |
ACRS 6.82 |
SHC 5.29 |
QGEN 4.93 |
MEDP 4.79 |
NEOG 3.19 |
RDNT 3.15 |
ICLR 2.91 |
IQV 2.31 |
XGN 1.54 |
MYGN 1.50 |
SYNH 1.34 |
FONR 0.00 |
BNR -3.25 |